Literature DB >> 18554859

Intra-operative imprint cytology for assessing the sentinel node in breast cancer: results of its routine use over 8 years.

K Contractor1, M Gohel, E Al-Salami, K Kaur, N Aqel, E Nigar, M Burke, H Singhal.   

Abstract

INTRODUCTION: Intra-operative imprint cytology (IIC) for analysing sentinel lymph node/s (SLN) in breast cancer allows definitive axillary surgery as a one-step procedure. Most reported studies are research oriented. This study reports long-term results of IIC done as routine clinical practice.
MATERIALS AND METHODS: Eight hundred ninety-six female, operable breast cancer patients underwent SLN biopsy over an 8-year period (January 1999-December 2006). Data were extracted retrospectively from medical records. SLNs were sent intra-operatively to the laboratory where they were bisected, touch imprinted and stained with Hematoxylin & Eosin. Patients with positive IIC had axillary clearance. Formal histological analyses of SLNs were compared with IIC findings. The impact of routine pre-operative axillary ultrasound (introduced in 2003) on IIC sensitivity and specificity was also assessed.
RESULTS: Median age was 61 years (26-89) and median tumour size was 18 mm (2-100). A total of 244/896 patients had SLN metastases on final paraffin histology of which 177 were correctly detected by IIC (67 false negatives). 39/67 false negatives could be attributed to sampling error. The overall sensitivity and specificity of IIC for the identification of SLN metastases was 73% and 100%, respectively. The sensitivity of IIC after introduction of pre-operative axillary ultrasound decreased from 75% to 71%. DISCUSSION: Routine use of IIC for analysis of the SLN in breast cancer allows complete axillary surgery during a single anaesthetic for a majority of patients undergoing SLN biopsy. Almost two thirds of positive axillae were spared a second operation. False negative results are frequent and patients should be warned about the potential need for further axillary surgery.

Entities:  

Mesh:

Year:  2008        PMID: 18554859     DOI: 10.1016/j.ejso.2008.04.005

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Intraoperative touch imprint cytology of sentinel lymph nodes in breast cancer: experience at a tertiary care center in Mexico.

Authors:  V M Pérez-Sánchez; T A Vela-Chávez; P Villarreal-Colin; E Bargalló-Rocha; M T Ramírez-Ugalde; D Munoz-Gonzalez; I Zeichner-Gancz
Journal:  Med Oncol       Date:  2009-03-19       Impact factor: 3.064

2.  The sensitivity and specificity of sentinel lymph node biopsy for breast cancer at Baylor University Medical Center at Dallas: a retrospective review of 488 cases.

Authors:  S Michelle Shiller; Robert Weir; John Pippen; Metin Punar; Daniel Savino
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-04

3.  Imprint cytology versus frozen section analysis for intraoperative assessment of sentinel lymph node in breast cancer.

Authors:  Thalia Petropoulou; Antonia Kapoula; Aikaterini Mastoraki; Aikaterini Politi; Eleni Spanidou-Karvouni; Ioannis Psychogios; Ioannis Vassiliou; Nikolaos Arkadopoulos
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-05-05

4.  The Diagnostic Accuracy of an Intraoperative Frozen Section Analysis and Imprint Cytology of Sentinel Node Biopsy Specimens from Patients with Uterine Cervical and Endometrial Cancer: a Retrospective Observational Study.

Authors:  Tomohito Tanaka; Shunsuke Miyamoto; Shinichi Terada; Yuhei Kogata; Satoe Fujiwara; Yoshimichi Tanaka; Kohei Taniguchi; Kazumasa Komura; Kazuhiro Yamamoto; Takashi Yamada; Masahide Ohmichi
Journal:  Pathol Oncol Res       Date:  2020-05-26       Impact factor: 3.201

5.  Intraoperative imprint cytology versus histological diagnosis for the detection of sentinel lymph nodes in breast cancer treated with neoadjuvant chemotherapy.

Authors:  Ronald Enrique Delgado-Bocanegra; Eduardo Camargo Millen; Cristina Moreira do Nascimento; Karine de Aguiar Bruno
Journal:  Clinics (Sao Paulo)       Date:  2018-08-02       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.